Diabetes and obesity drug prices and approvals in India
What the newer diabetes and obesity medicines cost in India and where they stand with the regulator. Every entry shows the date it was last checked. These same facts appear in the “In India” box of our reports.
Prices are indicative pharmacy prices and vary by brand, city and pharmacy. Last checked 13 November 2026. Spotted a change? Write to editor@diabesityrounds.com.
Jump to: Combination obesity drugs not approved · Finerenone · Injectable semaglutide · Insulin icodec · Oral semaglutide · Orforglipron · Orlistat · Resmetirom · SGLT2 inhibitors · Sitagliptin · Tirzepatide
Combination obesity drugs not approved in India
Naltrexone with bupropion, and phentermine with topiramate, are not approved in India.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
Finerenone in India
Finerenone was approved in India in April 2022 for chronic kidney disease with type 2 diabetes and launched by Bayer as Kerendia in August 2022; Sun Pharma sells a second brand, Lyvelsa. In November 2025 it was also approved in India for heart failure with mildly reduced or preserved ejection fraction. It is still under patent, with no generic. A 10 mg tablet costs about ₹100, so treatment runs at about ₹100 a day.
Checked 13 November 2026. Source: Bayer and Sun Pharma announcements; online pharmacy listing, checked 13 November 2026.
Injectable semaglutide in India
The Indian product patent on semaglutide expired on 20 March 2026 and a number of Indian manufacturers now make it. A separate formulation patent runs to 2031, so many Indian products come as vials or reusable cartridge pens. Most Indian semaglutide products are approved for type 2 diabetes rather than for weight; only a few carry a weight indication. Indian-made semaglutide runs from roughly ₹1,300 to about ₹8,000 a month depending on the manufacturer, presentation and dose. Indicative pen prices in September 2026 run from about ₹5,660 at 0.25 mg to about ₹8,999 at 2.4 mg; the dearer originator brand runs to about ₹16,400 at 2.4 mg.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
Insulin icodec in India
Insulin icodec (Awiqli) was launched in India on 9 July 2026 for adults with type 1 or type 2 diabetes who need basal insulin. A 700-unit pen costs ₹2,611, about ₹261 for a weekly dose of 70 units, against ₹345 to ₹453 for 70 units of the daily basal insulins on the Indian market.
Checked 13 November 2026. Source: Novo Nordisk India launch statements reported 9 July 2026, checked 13 November 2026.
Oral semaglutide in India
The oral semaglutide strengths sold in India are 3 mg, 7 mg and 14 mg, all approved for type 2 diabetes. The 25 mg strength approved for weight management in some other countries is not marketed in India. The originator tablet costs roughly ₹8,900 to ₹10,900 a month; Indian-made oral semaglutide costs roughly ₹3,000 to ₹7,600 a month.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
Orforglipron in India
An expert committee of India's national drug regulator has recommended import and marketing permission for orforglipron, but as of September 2026 there is no final approval and no launch in India.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
Orlistat in India
Orlistat costs roughly ₹450 to ₹1,350 a month in India, depending on the brand and the dose.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
Resmetirom in India
Resmetirom is not approved or marketed in India as of November 2026. Several Indian companies are running phase 3 trials in India after the national drug regulator's expert committee refused to waive local phase 3 data.
Checked 13 November 2026. Source: CDSCO expert committee recommendations and company statements, checked 13 November 2026.
SGLT2 inhibitors in India
Dapagliflozin and empagliflozin are both off patent in India and sold by many Indian manufacturers. Generic dapagliflozin 10 mg costs roughly ₹4 to ₹18 a tablet, against about ₹40 a tablet for the originator brand. The empagliflozin patent expired on 11 March 2025; generic empagliflozin launched from about ₹5.49 a tablet for 10 mg and ₹9.90 for 25 mg, against about ₹60 a tablet for the originator.
Checked 13 November 2026. Source: Company launch statements (Zydus 2020, Mankind 2025) and online pharmacy listings, checked 13 November 2026.
Sitagliptin in India
Sitagliptin went off patent in India in 2022 and is sold by many Indian manufacturers. At Jan Aushadhi Kendras a pack of 10 tablets costs ₹60 for 50 mg and ₹100 for 100 mg; sitagliptin with metformin costs ₹65 (50/500 mg) or ₹70 (50/1000 mg) for 10 tablets.
Checked 13 November 2026. Source: Department of Pharmaceuticals / PMBI statement, September 2022, checked 13 November 2026.
Tirzepatide in India
Tirzepatide is approved in India for adults with obesity, or with excess weight and a weight-related health problem, and for adults with type 2 diabetes. Indicative pharmacy prices in September 2026 run from about ₹13,125 a pen for the 2.5 mg starting dose to about ₹25,781 a pen for 15 mg. Single-dose vials of the 2.5 mg and 5 mg strengths cost about ₹3,281 and ₹4,101 each. For people with type 2 diabetes, tirzepatide has carried an approved cardiovascular indication since August 2026.
Checked 11 September 2026. Source: caspianhealthcare.in obesity medicines pages, reviewed 11 September 2026.
For registered medical practitioners. Not advice for individual patients, and not a price offer. See also our comparison pages and drug pages.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.